Daily Washington Insider
  • Business
  • World
  • Science
  • Investing

Daily Washington Insider

  • Business
  • World
  • Science
  • Investing
Investing

RAD 202 receives approval to start Phase 1 therapeutic trial

by admin December 20, 2024
December 20, 2024
RAD 202 receives approval to start Phase 1 therapeutic trial

Radiopharm Theranostics (RAD:AU) has announced RAD 202 receives approval to start Phase 1 therapeutic trial

Download the PDF here.

This post appeared first on investingnews.com

0
FacebookTwitterGoogle +Pinterest
previous post
5 Best-performing Canadian Nickel Stocks of 2024
next post
PRISM MarketView Features Q&A with President and CEO David Elsley: Cardiol Therapeutics Enters Phase 3 Clinical Trial for CardiolRx Addressing Patients with Recurrent Pericarditis

You may also like

Brunswick Exploration Once More Outlines a New, Major...

June 10, 2025

NexGen Signs First Uranium Contracts, Will Sell 5...

December 7, 2024

Opawica Announces the Closing of Non-Brokered Private Placement

December 21, 2024

SilverCrest Metals: Gold, Silver vs. Fiat — We...

May 31, 2024

Rio Tinto Spends Record AU$10.3 Billion with Western...

April 12, 2025

AI Market Forecast: Top Trends That Will Affect...

December 19, 2024

Canadian Critical Minerals

May 24, 2024

MXR: Extension of Takeover Offer Period

March 7, 2025

5 Top Weekly TSXV Stocks: Solis Rises 75...

July 15, 2024

Agreement to Acquire Major Drill-Ready Antimony-Gold-Tungsten Project in...

June 11, 2025

    Stay updated with the latest news, exclusive offers, and special promotions. Sign up now and be the first to know! As a member, you'll receive curated content, insider tips, and invitations to exclusive events. Don't miss out on being part of something special.


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Popular

    • 1

      Tartana Drilling to Verify Upgrading of 45,000 Tonne Copper Resource

    • 2

      Magic mushrooms effective for treating depression – study

    • 3

      Lancaster Resources Welcomes Three Highly Experienced Industry Experts to Its Advisory Board

    • 4

      Hong Kong plans to install thousands of surveillance cameras. Critics say it’s more proof the city is moving closer to China

    • 5

      UN experts urge Thailand not to deport dozens of Uyghurs to China where they face ‘real risk of torture’

    Categories

    • Business (1,228)
    • Investing (3,109)
    • Science (605)
    • World (3,677)
    Footer Logo

    Disclaimer: dailywashingtoninsider.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2024 dailywashingtoninsider.com | All Rights Reserved